Clinical Research

LVPEI's large patient volume combined with its applied research focus has made it an ideal site for clinical research. The multidisciplinary clinical research that is undertaken here is of international standards, with several projects sponsored by national funding agencies as well as multinational drug and device manufacturing companies. In recent years, LVPEI has become a key participant in a variety of multi-site clinical trials, apart from conducting intramural clinical research.

One of the primary areas of clinical research and one in which LVPEI has had a long history is contact lens studies. The suitability and safety of a variety of different contact lenses-antibacterial, extended wear, multi-focal, among others-is studied in target populations. This involves recruitment of volunteers and monitoring comfort levels and other factors related to use over time. These studies are done in collaboration with lens manufacturers as well as vision research groups across the globe.

Another area where LVPEI research teams have worked in tandem with the industry and other research organisations is in studying the efficacy, pharmacodynamics and related features of ophthalmic drugs and devices, including drug delivery systems.

All of LVPEI's clinical trials and other research involving human subjects are done with the approval and monitoring of an Institutional Review Board, which provides scientific and ethical oversight.


Clinical Research Project (KAR Campus) Hyderabad)
S No Name of the trial/Duration Principal Investigator Collaborator

 

A Phase 2/3, Randomized , Double Masked, Sham Controlled trial of QPI-1007 delivered by single or multi dose intravitreal injection(s) to subjects with acute non arteritic anterior Ischemic optic neuropathy (NAION)

Duration : 2016-2019
Dr. Ramesha K Quark Pharmaceuticals, Inc.

Clinical Research Project (Bhubaneswar Campus)
S No Name of the trial/Duration Principal Investigator Collaborator

 

A Phase 2/3, Randomized , Double Masked, Sham Controlled trial of QPI-1007 delivered by single or multi dose intravitreal injection(s) to subjects with acute non arteritic anterior Ischemic optic neuropathy (NAION)

Duration : 2016-2019
Dr Vivekanand Uttamrao Warkad Quark Pharmaceuticals, Inc.
TOP